Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma

Cancer Immunology, Immunotherapy · Published 2022-05-01 · Available online 20 Sep 2021 · Journal article · DOI 10.1007/s00262-021-03054-8 · PMID: 34545416 · PMC · Cited by 16 (Crossref)

Authors (3)

Jutatip Panaampon, Ryusho Kariya, Seiji Okada

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

71

Issue

5

Pages

1017-1031

Year

2022

Citation

Panaampon, J., Kariya, R., Okada, S. (2022). Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-03054-8

Related articles

• Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer · Investigational New Drugs · 2025 · Cites or is cited by this article
• Stealth designs to overcome allorejection in engineered cell therapy · Trends in Immunology · 2026 · Cites or is cited by this article
• Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus‐Associated Disorders · Cancer Reports · 2025 · Cites or is cited by this article
• Absence of CD38 expression in mantle cell lymphoma correlates with distinct pathological and genetic features · Human Pathology · 2026 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

16